Nobuhiko Kanaya

Dr. Nobuhiko Kanaya

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
NKNobuhiko Kanaya
Nobuhiko Kanaya
YKYohei Kitamura
Yohei Kitamura
MVMaria Lopez Vazquez
Maria Lopez Vazquez
AFArnaldo Franco
Arnaldo Franco
KCKok-Siong Chen
Kok-Siong Chen
KSKhalid Shah
Khalid Shah
Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metastasis mouse models and characterized them to be more immunosuppressive compared with primary melanoma, mimicking the clinical settings. Next, we developed an allogeneic twin stem cell (TSC) system composed of two tumor-targeting stem cell (SC) populations. One SC was loaded with oncolytic herpes simplex virus (oHSV), and the other SC was CRISPR-Cas9 gene-edited to knock out nectin 1 (N1) receptor (N1 KO ) to acquire resistance to oHSV and release immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Using mouse models of brain metastatic BRAF V600E /PTEN −/− and BRAF V600E/wt /PTEN −/− mutant melanomas, we show that locoregional delivery of TSCs releasing oHSV and GM-CSF (TSC-G) activated dendritic cell– and T cell–mediated immune responses. In addition, our strategy exhibited greater therapeutic efficacy when compared with the existing oncolytic viral therapeutic approaches. Moreover, the TSCs composed of SC-oHSV and SC N1KO –releasing GM-CSF and single-chain variable fragment anti–PD-1 (TSC-G/P) had therapeutic efficacy in both syngeneic and patient-derived humanized mouse models of leptomeningeal metastasis. Our findings provide a promising allogeneic SC-based immunotherapeutic strategy against melanomas in the CNS and a road map toward clinical translation.

5 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
YKYohei Kitamura
Yohei Kitamura
NKNobuhiko Kanaya
Nobuhiko Kanaya
SMSusana Moleirinho
Susana Moleirinho
WDWanlu Du
Wanlu Du
CRClemens Reinshagen
Clemens Reinshagen
KSKhalid Shah
Khalid Shah
Basal-like breast cancer (BLBC) shows brain metastatic (BM) capability and overexpresses EGFR and death-receptors 4/5 (DR4/5); however, the anatomical location of BM prohibits efficient drug-delivery to these targetable markers. In this study, we developed BLBC-BM mouse models featuring different patterns of BMs and explored the versatility of estem cell (SC)–mediated bi-functional EGFR and DR4/5-targeted treatment in these models. Most BLBC lines demonstrated a high sensitivity to EGFR and DR4/5 bi-targeting therapeutic protein, EVDRL [anti-EGFR VHH (EV) fused to DR ligand (DRL)]. Functional analyses using inhibitors and CRISPR-Cas9 knockouts revealed that the EV domain facilitated in augmenting DR4/5-DRL binding and enhancing DRL-induced apoptosis. EVDRL secreting stem cells alleviated tumor-burden and significantly increased survival in mouse models of residual-tumor after macrometastasis resection, perivascular niche micrometastasis, and leptomeningeal metastasis. This study reports mechanism based simultaneous targeting of EGFR and DR4/5 in BLBC and defines a new treatment paradigm for treatment of BM.

2 September 2023 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
YKYoshihiko Kakiuchi
Yoshihiko Kakiuchi
SKShinji Kuroda
Shinji Kuroda
NKNobuhiko Kanaya
Nobuhiko Kanaya
SKShunsuke Kagawa
Shunsuke Kagawa
HTHiroshi Tazawa
Hiroshi Tazawa
TFToshiyoshi Fujiwara
Toshiyoshi Fujiwara
Exosomes are cell-derived nanovesicles involved in cell-to-cell communications. These nanovesicles are generally considered to contain important carriers of information such as DNA and RNA, and show specific tropism. The combination of existing therapeutic agents with exosomes enhances therapeutic effects by increasing uptake into the tumor. Induction of immunogenic cell death (ICD) may also be triggered more strongly than with the drug alone. Oncolytic viruses (OVs) are even more effective as a drug in combination with exosomes. Although OVs are more likely to cause immune activity, combination with exosomes can exert synergistic effects. OVs have potent anti-tumor effects, but many limitations, such as being limited to local administration and vulnerability to attack by antibodies. Incorporation into exosomes can overcome these limitations and may allow effects against distant tumors. Novel therapies using exosomes are very attractive in terms of enhancing therapeutic efficacy and reducing side effects. This approach also contains elements overcoming disadvantages in OVs, which have not been used clinically until now, and may usher in a new era of cancer treatments.

19 November 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KCKok Siong Chen
Kok Siong Chen
SMSarah Manoury-Battais
Sarah Manoury-Battais
NKNobuhiko Kanaya
Nobuhiko Kanaya
IVIoulia Vogiatzi
Ioulia Vogiatzi
PBPaulo Borges
Paulo Borges
KSKhalid Shah
Khalid Shah
Recent progress in cancer cell–based therapies has led to effective targeting and robust immune responses against cancer. However, the inherent safety risks of using live cancer cells necessitate the creation of an optimized safety switch without hindering the efficacy of immunotherapy. The existing safety switches typically induce tolerogenic cell death, potentially leading to an immunosuppressive tumor immune microenvironment (TIME), which is counterproductive to the goals of immunotherapy. Here, we developed and characterized an inducible receptor-interacting protein kinase 3–driven (RIPK3-driven) necroptotic system that serves a dual function of safety switch as well as inducer of immunogenic cell death, which in turn stimulates antitumor immune responses. We show that activation of the RIPK3 safety switch triggered immunogenic responses marked by an increased release of ATP and damage-associated molecular patterns (DAMPs). Compared with other existing safety switches, incorporating the RIPK3 system inhibited tumor growth, improved survival outcomes in tumor-bearing mice, and fostered long-term antitumor immunity. Moreover, the RIPK3 system reinvigorated the TIME by promoting DC maturation, polarizing the macrophages toward a M1 phenotype, and reducing the exhaustion of CD4 + and CD8 + T lymphocytes. Our study highlights the dual role of the RIPK3-driven necroptotic system in improving the safety and efficacy of cancer cell–based therapy, with broader implications for cellular therapies.

22 January 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
NKNobuhiko Kanaya
Nobuhiko Kanaya
WSWaleed Khalid Seddiq
Waleed Khalid Seddiq
KCKok-Siong Chen
Kok-Siong Chen
YKYoshinori Kajiwara
Yoshinori Kajiwara
LLLucia Moreno Lama
Lucia Moreno Lama
KSKhalid Shah
Khalid Shah
Background: Immune checkpoint inhibitors have shown clinical benefit in non–small cell lung cancer–derived brain metastasis, but their efficacy in lung-to-leptomeningeal brain metastasis remains poor. Methods: A pair-matched RNA expression dataset of patients with non–small cell lung cancer and brain metastases was analyzed to identify brain metastasis–specific suppressive tumor microenvironment features. Next, we created immune-competent lung-to-leptomeningeal brain metastasis mouse models that mimic clinical lung-to-leptomeningeal brain metastasis. We evaluated the efficacy of intrathecal delivery of allogeneic stem cells engineered to release single-chain variable part of the antigen-binding fragment (scFv) anti–programmed cell death 1 protein (PD-1). To enhance tumor cell killing and subsequent modulation of the immune tumor microenvironment, we explored the therapeutic activity of dual stem cells releasing oncolytic herpes simplex virus (oHSV) and scFvPD-1 and profiled immune and metabolic consequences. Results: RNA sequencing analysis of primary non–small cell lung cancer and brain metastases revealed an immune-suppressive tumor microenvironment with reduced immune cells and increased PD-1–positive T cells in brain metastases. We showed decreased immune cells and increased PD-1–positive T cells in the tumor microenvironment of lung-to-leptomeningeal brain metastases compared with primary non-small cell lung cancer in lung-to-leptomeningeal brain metastasis mouse models. Next, we showed that locoregional intrathecal treatment with stem cells releasing scFvPD-1 but not conventional systemic injection of anti–PD-1 antibodies suppressed tumor growth and improved survival in our immune-competent lung-to-leptomeningeal brain metastasis models. Furthermore, dual–stem cells releasing oHSV and scFvPD-1 enhanced therapeutic outcomes by inducing oHSV–mediated immunogenic cell death, activating antitumor T-cell signaling, and disrupting oxidative phosphorylation, all of which sensitized tumors to cisplatin. Conclusion: Locoregional delivery of dual–stem cells releasing oHSV/scFvPD-1 effectively targets the immune-suppressive tumor microenvironment in lung-to-leptomeningeal brain metastasis, providing a promising strategy for treating lung-to-leptomeningeal brain metastases.

6 December 2012 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HAHideki Aoki
Hideki Aoki
TMToshiaki Morihiro
Toshiaki Morihiro
TATakashi Arata
Takashi Arata
NKNobuhiko Kanaya
Nobuhiko Kanaya
STShou Takeda
Shou Takeda
HTHitoshi Takeuchi
Hitoshi Takeuchi